Literature DB >> 552296

Plasma propranolol concentrations and the erythrocyte sedimentation rate.

R E Schneider, H Bishop, C F Hawkins.   

Abstract

1. The plasma propranolol concentrations after a single oral dose of 40 mg were measured in 25 patients with rheumatoid arthritis and compared with those of 16 patients with Crohn's disease from a previous study. Thirteen healthy volunteers were used as controls. 2. In both diseases some high and some low values occurred. This scatter did not correlate with any symptoms or biochemical or haematological data other than with the erythrocyte sedimentation rate (ESR). 3. Both sets of patients were therefore separated into two groups depending on whether or not their ESRs were above or below 20 mm/l h. In both diseases the plasma propranolol concentrations of the patients with a raised ESR were significantly higher than the controls as well as those of the low ESR group. 4. In rheumatoid arthritis the plasma propranolol concentrations of the patients with a low ESR did not differ from those of the controls, but in Crohn's disease they remained significantly higher. 5. In one patient with Crohn's disease there was a dramatic rise in propranolol concentrations during an exacerbation (ESR 91 mm/l h) compared with those during a remission (ESR 20 mm/l h). 6. A difference in smoking habits did not seem to have been responsible for the difference in plasma propranolol concentrations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 552296      PMCID: PMC1429715          DOI: 10.1111/j.1365-2125.1979.tb05907.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Relationship of the acid micro-climate in rat and human intestine to malabsorption.

Authors:  M L Lucas; J A Blair; B T Cooper; W T Cooke
Journal:  Biochem Soc Trans       Date:  1976       Impact factor: 5.407

2.  Absorption of drugs from the rat small intestine.

Authors:  L S SCHANKER; D J TOCCO; B B BRODIE; C A HOGBEN
Journal:  J Pharmacol Exp Ther       Date:  1958-05       Impact factor: 4.030

3.  Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn's disease.

Authors:  R E Schneider; J Babb; H Bishop; M Mitchard; A M Hoare
Journal:  Br Med J       Date:  1976-10-02

4.  The influence of smoking on the intersubject variation in pentazocine elimination.

Authors:  D P Vaughan; A H Beckett; D S Robbie
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

5.  Propranolol absorption in Crohn's disease and coeliac disease.

Authors:  B T Cooper; W T Cooke; M L Lucas; J A Blair
Journal:  Br Med J       Date:  1976-11-06

6.  The disposition of propranolol. I. Elimination during oral absorption in man.

Authors:  D G Shand; R E Rangno
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

7.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

8.  Letter: Plasma-propranolol levels in inflammation disease.

Authors:  J Babb; H Bishop; R E Schneider; C F Hawkins; A M Hoare
Journal:  Lancet       Date:  1976-06-26       Impact factor: 79.321

9.  Contribution of individual differences in gastric emptying to variability in plasma propranolol concentrations.

Authors:  C M Castleden; C F George; M D Short
Journal:  Br J Clin Pharmacol       Date:  1978-02       Impact factor: 4.335

  9 in total
  12 in total

Review 1.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

2.  Intravenous propranolol in patients with inflammation.

Authors:  D G Waller; C L Smith; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

3.  beta-blocker plasma concentrations and inflammatory disease: clinical implications.

Authors:  R E Schneider; H Bishop
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

4.  Effect of age on plasma propranolol levels.

Authors:  R E Schneider; H Bishop; R A Yates; C P Quarterman; M J Kendall
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

5.  Bupivacaine kinetics during hyperthermia in rats.

Authors:  B Bruguerolle; X Roucoules; L Attolini; A M Lorec
Journal:  Can J Anaesth       Date:  1994-03       Impact factor: 5.063

6.  Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart.

Authors:  Saeed Sattari; William F Dryden; Lise A Eliot; Fakhreddin Jamali
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

7.  Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

Authors:  P A Soons; C Grib; D D Breimer; W Kirch
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

8.  Selective effect of adjuvant arthritis on the disposition of propranolol enantiomers in rats detected using a stereospecific HPLC assay.

Authors:  M Piquette-Miller; F Jamali
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

9.  Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers.

Authors:  J Vanakoski; T Seppälä
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 10.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.